Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 11/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
| ▸ | POLG | P54098 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23620978 | 1.00 | STING1 (0.37) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL26019436 | 1.00 | STING1 (0.37) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL23620958 | 1.00 | STING1 (0.37) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL23620914 | 0.93 | STING1 (0.33) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL26019431 | 0.93 | STING1 (0.33) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL23620966 | 0.93 | STING1 (0.33) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL23620912 | 0.93 | STING1 (0.33) | STING1PDE3ALMNACACNA1FALB | |
| SCHEMBL26019340 | 0.92 | STING1 (0.35) | STING1 | |
| SCHEMBL26019334 | 0.92 | STING1 (0.35) | STING1 | |
| SCHEMBL26019338 | 0.92 | STING1 (0.35) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | MSD INTERNATIONAL GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | SLC10A1, PNP, PYGL | STING1 1665/4885PDE3A 319/4885LMNA 1820/4885 |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | SLC10A1, PNP, PYGL | STING1 1665/4885PDE3A 319/4885LMNA 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.